BR9814857A - Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril - Google Patents

Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril

Info

Publication number
BR9814857A
BR9814857A BR9814857-5A BR9814857A BR9814857A BR 9814857 A BR9814857 A BR 9814857A BR 9814857 A BR9814857 A BR 9814857A BR 9814857 A BR9814857 A BR 9814857A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
sterile pharmaceutical
leukemia
lymphoma
human
Prior art date
Application number
BR9814857-5A
Other languages
English (en)
Inventor
Raymond P Warrel Jr
Pier Paolo Pandolfi
Janice L Gabrilove
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22057410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9814857(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of BR9814857A publication Critical patent/BR9814857A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"PROCESSOS PARA TRATAR LEUCEMIA, CâNCER SóLIDO ELEUCEMIA, LINFOMA OU TUMORES SóLIDOS EM UMHUMANO,E PARA FABRICAR UMA COMPOSIçãOFARMACêUTICA ESTéRIL, E, A RESPECTIVA COMPOSIçãOFARMACêUTICA ESTéRIL". A invenção se refere ao uso decompostos arsênicos para tratar uma variedade de leucemias,linfomas e tumores sólidos. Ademais, os compostos arsênicospodem ser usados em combinação com outros agentesterapêuticos tais como um retinóide. A invenção também prevê umprocesso para produzir formulações de trióxido arsênico.
BR9814857-5A 1997-11-10 1998-11-10 Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril BR9814857A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6465597P 1997-11-10 1997-11-10
PCT/US1998/024024 WO1999024029A1 (en) 1997-11-10 1998-11-10 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol

Publications (1)

Publication Number Publication Date
BR9814857A true BR9814857A (pt) 2001-12-26

Family

ID=22057410

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814857-5A BR9814857A (pt) 1997-11-10 1998-11-10 Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril

Country Status (20)

Country Link
US (22) US6770304B2 (pt)
EP (3) EP2255800B1 (pt)
JP (2) JP2001522799A (pt)
KR (1) KR20010031938A (pt)
CN (1) CN1285743A (pt)
AU (1) AU747474C (pt)
BR (1) BR9814857A (pt)
CA (1) CA2309652C (pt)
CY (1) CY1113856T1 (pt)
DK (1) DK2255800T3 (pt)
ES (2) ES2399480T3 (pt)
HK (1) HK1150762A1 (pt)
ID (1) ID25622A (pt)
IL (1) IL136051A0 (pt)
NO (1) NO20002409L (pt)
NZ (1) NZ504585A (pt)
PL (1) PL343868A1 (pt)
PT (2) PT2255800E (pt)
TR (1) TR200002243T2 (pt)
WO (1) WO1999024029A1 (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044559C (zh) * 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
CA2307208A1 (en) 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
ES2399480T3 (es) * 1997-11-10 2013-04-01 Memorial Sloan-Kettering Cancer Center Procedimiento de producción de formulaciones de trióxido de arsénico
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
KR100272835B1 (ko) * 1998-05-08 2000-11-15 배일주 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물
KR100399657B1 (ko) * 2000-06-29 2003-09-29 배일주 혈관신생 억제제
DK1309627T3 (da) * 2000-08-08 2009-12-21 Immunomedics Inc Immunoterapi for kronisk myelocytisk leukæmi med nögent anti-NCA-90-antistof
CN1332672C (zh) * 2001-03-15 2007-08-22 张鹏 一种三氧化二砷注射粉剂
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
US20040110691A1 (en) * 2001-11-13 2004-06-10 Stamler Jonathan S. Thiol reactive agents as a therapeutic modality
KR20030058019A (ko) * 2001-12-29 2003-07-07 한국원자력연구소 삼산화비소(Ａｓ₂Ｏ₃)를 유효 성분으로 포함하는 방사선치료증진제
EP2420229A1 (en) 2002-01-07 2012-02-22 Board Of Regents, University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
KR20030075017A (ko) * 2002-03-15 2003-09-22 한국원자력연구소 삼산화비소를 포함하는 혈관신생억제제
US8394422B2 (en) 2002-04-26 2013-03-12 Centre National De La Recherche Scientifique (Cnrs) Arsenic therapy for autoimmune and/or inflammatory diseases in mice and humans
FR2838965B1 (fr) 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
EP1356820A1 (en) * 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) DNA vaccine combined with an inducer of tumor cell apoptosis
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
US8906422B2 (en) * 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US20080089949A1 (en) * 2006-10-13 2008-04-17 Yok-Lam Kwong Method for treating cancer using oral arsenic trioxide
US20080166425A1 (en) * 2002-10-09 2008-07-10 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
TWI296527B (en) 2003-04-23 2008-05-11 Inst Of Nuclear Energy Res Rocaec Radioactive aesenic-containing compounds and their uses in the treatment of tumors
GB0317020D0 (en) * 2003-07-21 2003-08-27 Sahajanand Biotech Private Ltd Herbo-mineral formulation for refractory leukemias and lymphomas
CN1304053C (zh) * 2003-08-13 2007-03-14 上海第二医科大学附属瑞金医院 一种可治愈急性早幼粒细胞白血病的组合药物
FR2860719B1 (fr) * 2003-10-10 2006-04-28 Assist Publ Hopitaux De Paris Utilisation de derives organoarsenies ou organostibiques pour leurs proprietes anticancereuses
KR100632250B1 (ko) 2004-02-16 2006-10-11 정태호 비소 화합물을 유효성분으로 하는 항암제
US20050196464A1 (en) * 2004-03-03 2005-09-08 Tty Biopharm Company Limited Method and pharmaceutical composition for treatment of skin neoplasm
TW201440760A (zh) 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20060292243A1 (en) * 2005-06-24 2006-12-28 Shao-Chi Hsin Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases
JP4994374B2 (ja) 2005-07-29 2012-08-08 ジオファーム オンコロジー， インコーポレイテッド がんを治療するための化合物および方法
US20070134349A1 (en) * 2005-09-19 2007-06-14 Duke University Methods of treating hematological malignancies
US20080233207A1 (en) * 2006-01-04 2008-09-25 Sheptovitsky Yelena G Injectable and Infusable Mercury Compositions and Methods for Treating Cancer
CN104109177A (zh) 2006-01-13 2014-10-22 得克萨斯州A&M大学系统 用于治疗癌症的化合物和方法
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
US20080089951A1 (en) * 2006-10-11 2008-04-17 The University Of Hong Kong Method for Inhibiting Cancer Using Arsenic Trioxide
KR101009893B1 (ko) * 2007-04-06 2011-01-20 주식회사 엘지화학 고순도 헤테로폴리산의 신규한 제조방법
EP2209480B1 (en) * 2007-11-02 2012-09-05 Ziopharm Oncology, Inc. Combination therapy with organic arsenicals
CA2705467A1 (en) * 2007-12-12 2009-06-18 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
US8650648B2 (en) 2008-03-26 2014-02-11 Sophos Limited Method and system for detecting restricted content associated with retrieved content
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
EP2321012B1 (en) 2008-08-20 2018-10-10 Solasia Pharma K.K. Organoarsenic compounds and methods for the treatment of cancer
TR201905548T4 (tr) * 2009-09-10 2019-05-21 Kominox Inc Kanser kök hücresi hedefli ve ilaç dirençli kanser terapisi.
US8795738B2 (en) 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
EP2752913B1 (en) * 2012-03-30 2016-11-23 Panasonic Intellectual Property Management Co., Ltd. Cylindrical battery
ES2641847T3 (es) 2012-09-20 2017-11-14 Yogesh Narayan BENDALE Proceso para biosintetizar nanotrióxido de arsénico y su uso en el tratamiento de enfermedades que incluyen el cáncer
CN104884077B (zh) * 2012-10-08 2019-02-12 上海泽生科技开发股份有限公司 治疗糖尿病患者心力衰竭的组份和方法
WO2015101618A1 (en) * 2013-12-30 2015-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia
ES2954081T3 (es) 2015-01-29 2023-11-20 Eupharma Pty Ltd Composiciones que contienen arsénico para el uso en métodos de tratamiento
EP3981414A1 (en) 2015-02-01 2022-04-13 Syros Pharmaceuticals, Inc. High surface-area lyophilized compositions comprising arsenic for oral administration in patients
KR102015858B1 (ko) * 2015-10-23 2019-08-30 손영태 법제된 비상을 함유하는 면역력 증강을 위한 약학적 조성물
KR102548836B1 (ko) 2016-02-25 2023-07-03 삼성디스플레이 주식회사 표시 장치
US9700580B1 (en) * 2016-06-14 2017-07-11 Marguerite Harning Method for cancer treatment
AU2017368444B9 (en) 2016-12-01 2020-07-02 Eupharma Pty Ltd Arsenic compositions
KR101844050B1 (ko) 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
CN113491710A (zh) * 2017-02-24 2021-10-12 四川兴科蓉药业有限责任公司 β-As4S4在制备用于治疗血液系统恶性肿瘤的药物中的用途
WO2019109095A1 (en) * 2017-12-01 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders
GB201800736D0 (en) * 2018-01-17 2018-02-28 St Georges Hospital Medical School Combination therapy for treatment of leukemia
WO2020117868A1 (en) * 2018-12-03 2020-06-11 Beth Israel-Deaconess Medical Center, Inc. Arsenic compounds and retinoic acid compounds for treatment of idh-associated disorders
WO2020117867A1 (en) * 2018-12-03 2020-06-11 Beth Israel-Deaconess Medical Center, Inc. Darinaparsin and retinoic acid compounds for treatment of idh-associated disorders
CN110101713A (zh) * 2019-05-16 2019-08-09 上海交通大学医学院附属第九人民医院 一种三氧化二砷组合物的应用
CN112675197A (zh) * 2021-01-22 2021-04-20 中山大学孙逸仙纪念医院 一种用于儿童Hedgehog信号通路驱动肿瘤的药物组合物
US11583552B2 (en) * 2021-02-17 2023-02-21 Manoj Maniar Pharmaceutical formulation of arsenic trioxide
CN117137932B (zh) * 2023-10-18 2024-04-19 中国中医科学院中药研究所 一种用于肿瘤的中药复方制剂及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132275A (en) 1872-10-15 Improvement in medical compounds
US232807A (en) 1880-10-05 Herbert e
US3700498A (en) 1970-12-10 1972-10-24 Ibm Process for making electrophotographic plates
JPS5188620A (en) 1975-01-31 1976-08-03 Jintainokenkonoiji kotonigannitaishitekonoojusuru noshukuionekinoseizoho
DE3003635C2 (de) 1980-02-01 1985-07-11 Klöckner-Humboldt-Deutz AG, 5000 Köln Verfahren und Vorrichtung zur Entarsenierung arsenhaltiger Materialien
US4501275A (en) * 1981-07-06 1985-02-26 Maahs Jerry D Mammalian subject heating unit using radiant heat
FR2539993A1 (fr) 1983-01-28 1984-08-03 Darcheux Mario Baume agissant sur les plaies cancereuses
US4950768A (en) 1984-01-16 1990-08-21 Cronyn Marshall W Cyclic disulfonic ester cross-linking compounds
US4696814A (en) * 1985-08-21 1987-09-29 Warner-Lambert Company Parenteral phenytoin compositions
US4705030A (en) * 1987-02-17 1987-11-10 Tepperberg Phillip S Hand augmenting spinal manipulator encircling the hand
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
CN1061908A (zh) 1991-12-21 1992-06-17 江西省妇产医院 一种治癌药物的制造方法
CN1060935C (zh) 1992-05-31 2001-01-24 丛繁滋 用于癌病灶直接给药的砷制剂的制备方法
CN1044777C (zh) 1992-07-06 1999-08-25 杨世泽 癌痛止痛膏的配制方法
MX9304501A (es) * 1992-07-24 1994-04-29 Univ Johns Hopkins Quimioterapia para cancer.
DE4224534A1 (de) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4317331A1 (de) 1993-05-25 1994-12-01 Reischle Karl Georg Behandlung von Schädigungen des Immunsystems
ITTO930510A1 (it) 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
DE69434093T2 (de) 1994-02-18 2006-03-09 Tamara Vasilievna Vorobieva Substanz mit immunonodulierender wirkung und zur verringerung der disfunktion des gewebezellenregelungssystems
US5646159A (en) 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
CN1119113A (zh) 1994-09-22 1996-03-27 衣永德 复方癌复康胶囊及制备方法
CN1122700A (zh) 1994-11-08 1996-05-22 付知中 一种治疗乳腺疾病、肿瘤疮毒的散剂及其制备方法
LV11667B (en) 1995-08-14 1997-06-20 Tamara Vorobieva Remedy for renewal of disordered function of immunomodulation and cell tissue reproduction adjustors
CN1044559C (zh) 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
KR100401220B1 (ko) 1995-09-12 2004-03-20 더 리포좀 컴퍼니, 인코퍼레이티드 가수분해를촉진시키는소수성탁산유도체
CN1058620C (zh) 1995-11-12 2000-11-22 卢颖 一种治疗癌症的外用中成药及配备生产工艺
CN1052648C (zh) 1995-12-03 2000-05-24 唐书生 癌瘤消肿止痛膏
CA2307208A1 (en) 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
AU2002300339B2 (en) 1997-11-10 2006-03-02 Sloan-Kettering Institute For Cancer Research Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
AU2006202364B2 (en) 1997-11-10 2009-05-28 Sloan-Kettering Institute For Cancer Research Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
ES2399480T3 (es) 1997-11-10 2013-04-01 Memorial Sloan-Kettering Cancer Center Procedimiento de producción de formulaciones de trióxido de arsénico
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法

Also Published As

Publication number Publication date
US6884439B2 (en) 2005-04-26
US20030099719A1 (en) 2003-05-29
NO20002409L (no) 2000-06-27
US20040146574A1 (en) 2004-07-29
US20020013371A1 (en) 2002-01-31
US20040146570A1 (en) 2004-07-29
EP1037625A1 (en) 2000-09-27
US6861076B2 (en) 2005-03-01
US6723351B2 (en) 2004-04-20
US20040146569A1 (en) 2004-07-29
CY1113856T1 (el) 2016-07-27
US20110091573A1 (en) 2011-04-21
IL136051A0 (en) 2001-05-20
US20040146577A1 (en) 2004-07-29
US20040151782A1 (en) 2004-08-05
ID25622A (id) 2000-10-19
AU747474B2 (en) 2002-05-16
AU1397399A (en) 1999-05-31
US6855339B2 (en) 2005-02-15
US6982096B2 (en) 2006-01-03
US20040146580A1 (en) 2004-07-29
US20060029681A1 (en) 2006-02-09
NO20002409D0 (no) 2000-05-09
EP2255800A1 (en) 2010-12-01
JP2010184926A (ja) 2010-08-26
NZ504585A (en) 2002-06-28
EP1964557A1 (en) 2008-09-03
US20040146573A1 (en) 2004-07-29
US20040146583A1 (en) 2004-07-29
US20040146572A1 (en) 2004-07-29
US20040146579A1 (en) 2004-07-29
US20040146576A1 (en) 2004-07-29
CA2309652C (en) 2013-01-29
US20040146582A1 (en) 2004-07-29
US6770304B2 (en) 2004-08-03
JP2001522799A (ja) 2001-11-20
TR200002243T2 (tr) 2000-12-21
US20040146578A1 (en) 2004-07-29
EP1964557B1 (en) 2013-01-02
EP2255800B1 (en) 2012-10-17
US8273379B2 (en) 2012-09-25
HK1150762A1 (en) 2012-01-13
PT1964557E (pt) 2013-02-20
US7879364B2 (en) 2011-02-01
KR20010031938A (ko) 2001-04-16
ES2395515T3 (es) 2013-02-13
WO1999024029A1 (en) 1999-05-20
EP1037625A4 (en) 2002-07-31
US20040146571A1 (en) 2004-07-29
CA2309652A1 (en) 1999-05-20
US20040146575A1 (en) 2004-07-29
ES2399480T3 (es) 2013-04-01
CN1285743A (zh) 2001-02-28
AU747474C (en) 2006-09-21
PL343868A1 (en) 2001-09-10
US20030211171A1 (en) 2003-11-13
US20040146568A1 (en) 2004-07-29
PT2255800E (pt) 2012-12-17
DK2255800T3 (da) 2013-02-04
US20040146581A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
BR9814857A (pt) Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril
MY121548A (en) Compounds and methods for the treatment of cancer
MX172600B (es) , "procedimiento para la produccion de una proteina biologicamente activa
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
ATE199167T1 (de) Nichtglykosyliertes fgf-4 und dieses enthaltende präparate
PT88275A (pt) Processo para a preparacao de composicoes farmaceuticas contendo 5-amino ou amino substituido-1,2,3-triazois uteis como agentes antiproliferativos
ES468525A1 (es) Procedimiento para la obtencion de nuevas 2-alquilenaminodi-hidropiridinas
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
GB2188547B (en) Tamoxifen composition for the treatment of psoriasis.
ES2144054T3 (es) Complejos de tri(platino).
AU533524B2 (en) 6-substituted-11-alkylene morphanthridines
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
DE69612056T2 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
NO873934D0 (no) Fremgangsmaate for forbedret saarheling.
ATE22282T1 (de) Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen.
DK277387A (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
DE69009765T2 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3879709D1 (de) Platin-arzneimittel.
DE3782661T2 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs.
ES2072431T3 (es) D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.
BR9810930A (pt) Composições farmacêuticas de arglabina e derivados de arglabina
BR9903472A (pt) Proceso de obtenção das ligninas tetraidrofurânicas veraguensina (1) e grandisina (2), atividade antichagásica e seu uso como anthichagásico

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE ESTA EM DESACORDO COM OS ARTIGOS 8O, 10 ( INCISO V III ), 11 E 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]